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ABSTRACT
Despite numerous developed drugs based on glucose metabolism interventions 
for treatment of age-related diseases such as diabetes neuropathies (DNs), DNs are 
still increasing in patients with type 1 or type 2 diabetes (T1D, T2D). We aimed to 
identify novel candidates in adipose tissue (AT) and pancreas with T2D for targeting 
to develop new drugs for DNs therapy.
AT-T2D displayed 15 (e.g. SYT4 up-regulated and VGF down-regulated) and 
pancreas-T2D showed 10 (e.g. BAG3 up-regulated, VAV3 and APOA1 down-regulated) 
highly differentially expressed genes with neuronal functions as compared to control 
tissues. ELISA was blindly performed to measure proteins of 5 most differentially 
expressed genes in 41 human subjects. SYT4 protein was upregulated, VAV3 and APOA1 
were down-regulated, and BAG3 remained unchanged in 1- Obese and 2- Obese-T2D 
without insulin, VGF protein was higher in these two groups as well as in group 3- Obese-
T2D receiving insulin than 4-lean subjects. Interaction networks analysis of these 5 
genes showed several metabolic pathways (e.g. lipid metabolism and insulin signaling).
Pancreas is a novel site for APOA1 synthesis. VGF is synthesized in AT and 
could be considered as good diagnostic, and even prognostic, marker for age-
induced diseases obesity and T2D. This study provides new targets for rational drugs 
development for the therapy of age-related DNs.
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INTRODUCTION
The homeostasis of blood glucose levels is 
maintained by both insulin and glucagon synthesis, which 
is functionally tightly regulated by the pancreatic β-cells 
and α-cells respectively. When blood glucose levels rise 
(hyperglycemia), pancreatic β-cells synthesize and secrete 
insulin to the bloodstream to regulate glucose levels. On 
the contrary, when circulating glucose levels fall below 
normal values (hypoglycemia), pancreatic α -cells produce 
and release glucagon to the bloodstream to tune up glucose 
concentrations via conversion of stored glycogen into 
glucose and its release into the circulation [1, 2]. Thus, 
a disruption in blood glucose regulation leads to the 
hyperglycemia state so-called diabetes. There are two 
types of aged-related [3, 4] diabetes; type 1 diabetes (T1D) 
and type 2 diabetes (T2D). Diminished or dysregulation of 
insulin by β-cells in T1D and T2D respectively are caused 
by cell aging process. T1D is an autoimmune disease 
that pancreatic β-cells are targeted to be broken down by 
antibodies produced by immune B cells. In this regard, the 
main production site of insulin is diminished by β-cells 
[5–9]. In contrast, in age-related-T2D the pancreatic β-cells 
are still active and do synthesize insulin but at dysregulated 
levels and not sensitive enough [10–13]. In a normal state, 
there is a homeostatic balance and cross talk between 
skeletal muscle, liver and adipose tissue (AT) organs with 
respect to glucose levels, which is strictly under control 
of insulin [14]. In this regard, insulin 1- promotes glucose 
uptake and inhibits lipolysis by the skeletal muscle, 2- 
stimulates glycogenesis and suppress glucose formation 
and release from the liver, and 3- stimulates adipogenesis 
and prevent lipolysis in AT-associated adipocytes [14]. In an 
obese state, insulin shows a function completely opposite 
to the normal state in these three organs. Moreover, it has 
been recently shown that other cells such as adipocytes, 
macrophages also synthesize insulin [15]. Patients with 
either T1D or T2D diabetes are at high risk for serious 
complications such as cardiovascular diseases (CVDs) 
[16] and diabetic neuropathy (DN) [17–23]. Obesity 
plays an important role in the development of T2D and its 
complications via the promotion of an inflammatory state 
[16]. In this regard, Systems biology could be a solution to 
find etiology of aged-related diseases such as T1D, T2D, 
neurodegenerative and cardiovascular diseases [24].
DNs are the most common micro-vascular 
complications that occur in both T1 and T2 diabetes 
(40–60%) [18–20, 25, 26]. DNs-associated syndromes are 
classified into two groups; diffuse and focal. The former 
neuropathies are usually chronic and more common among 
diabetic patients, while focal neuropathies are acute [25]. 
In general, DNs occur in progressive damages of neuronal 
cells that commonly appear with symptoms such as severe 
pain, loss of sensation and disability [19, 22, 25].
Despite the general agreement that hyperglycemia 
plays a key role in initiation and development of DNs, 
the underlying mechanisms for the development of DNs 
is unknown and remains to be investigated [19, 22, 27]. 
Numerous studies have shown that hyperglycemia leads 
to the overload of electron transport chain in mitochondria 
and subsequent oxidative stress. The imbalance in the 
mitochondrial redox state, in favor of oxidation conditions, 
leads to the accumulation of reactive oxygen species 
(ROS). Subsequently, oxidative stress affects several 
metabolic pathways [such as insulin signaling pathway 
and protein kinase C (PKC) pathway; advanced glycation 
end products (AGEs) and mitogen activated protein 
kinase (MAPKs)] associated with glucose metabolism 
with enhanced oxidative stress and, in turn, inflammatory 
reactions [20, 21, 25, 28–32].
Although numerous drugs and therapies have been 
proposed to treat the DNs, the majority of these drugs and 
treatments were restricted to target the redox and glucose 
metabolic pathways [20, 32]. None of the drugs that 
targeted glucose metabolic pathways showed any efficient 
effect in the treatment of DNs [19, 22]. Also, despite 
identification of the genes [19] and metabolic pathways 
associated with DNs, the molecular causes of DNs events 
still occur in a large scale. These studies suggest that beside 
hyperglycemia other genetic components and factors may 
contribute to the development of DNs. For instance, tight 
links between oxidative stress and obesity were recently 
reported, which may provide new insight for investigation 
of the genes associated with DNs [21]. Meijer et al. have 
recently shown that metabolic dysfunction leads to the 
adipocytes hypertrophy (the main cause of obesity), 
which primes inflammation in AT [15, 16] and, in turn, 
is implicated in pathophysiological states such as energy 
storage disruption within adipocytes (e.g. triglycerides 
breakdown, FFAs, glycerol et cetera), insulin resistance 
(IR), and hyperglycemia as hallmark of T2D.
Feldman et al. reported several pathways involved 
in lipid, carbohydrate and energy metabolism modulating 
gene expression patterns in peripheral nerves on BKS db/
db mouse sciatic nerve. Although this study support the 
hypothesis that hyperglycemia play an important role in 
nerve damage, lipid metabolism may involve neuronal 
damage and development of DNs as well [19]. Since both 
pancreas and AT are key tissues involved in age-induced 
T2D and its complications, this study was designed to 
investigate whether T2D alters the expression of genes with 
a function in neuronal processes in human pancreas and AT 
and that might be implicated in the insurgence of DNs.
RESULTS
The effect of type 2 diabetes on genes with a 
neuronal function
Pancreas
To investigate whether there are genes with a 
neuronal function that could show highly and clear 
changes in expression and that caused by age-induced 
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T2D, we measured mRNA expression in human pancreas 
and adipose tissue (AT) with T2D. As depicted in Table 1 
and Figure 1, two genes OLIG1 and BAG3 were highly 
up-regulated and eight genes PRDM16, GLDNA, APOA1, 
CCKBR, EDN3, VAV3, CXCR4, and GHRL were down 
regulated in pancreas with T2D as compared to pancreas 
control. Based on Gene Ontology database search, 
OLIG1 gene shows functions in neuron fate commitment, 
neurogenesis, generation of neurons, and neuron 
differentiation as shown in Figure 2. Based on database 
search, BAG3 gene showed only a neural function 
(i.e. neuron part). There were 24 neuron functions found 
for these 10 genes in pancreas of which chemokine 
C-X-C receptor (CXCR4) gene was shown to have a role 
in 17 neural functions based on Gene Ontology database 
(Figure 2). Among eight down-regulated genes in pancreas 
with T2D, VAV3 gene was highest down-regulated gene 
with approximately 246-fold (Table 1 and Figure 1).
Adipose tissue (AT)
The expression of 15 genes were found to be highly 
altered in AT caused by age-induced T2D (Table 2 and 
Figure 3). From these 15 genes, 8 gens were highly up-
regulated and 7 genes highly down-regulated (Table 2, 
and Figure 3). The expression of synaptotagmin-4 (SYT4) 
gene were tremendously high up-regulated (approximately 
392-fold) in AT-T2D as compared to AT-control, while 
VGF (neurosecretory protein) is highly down-regulated 
(approximately 119-fold) Table 2 and Figure 3). Another 
gene, which is very highly up-regulated in AT-T2D as 
compared to AT-control was MYRF (Myelin regulatory 
factor) as displayed in Table 2 and Figure 3. The fold 
changes of all 15 genes were reported in Table 2. Based on 
Gene Ontology database search, 52 neural functions were 
found for these 15 genes (Figure 4). Although VGF gene 
was highly down-regulated, only one neural function (i.e. 
neuropeptide hormone activity) was shown to be linked 
with this gene (Figure 4). SYT4 gene showed a link with 
5 neural functions; 1- neurological system process, 2- 
neurotransmitter secretion, 3- neurotransmitter transport 
4- neuron part and 5- neuron projection. Based on Gene 
Ontology search, PTN and LRNN4 genes showed only 
link with one neural function (Figure 4) and both genes 
were up-regulated, while the other genes showed multiple 
neural functions.
Pathway analysis
The in-silico functional analysis conducted on 
the list of 25 genes, led to the identification of several 
molecule-function/disease connections, as shown in 
Figure 5. Focusing on SYT4, VGF, BAG3, APOA1, and 
VAV3 and on their tightly related interactors, which in 
turn participated to lipid metabolism, insulin, protein 
kinase C (PKC), advanced glycation end (AGE) products 
and MAPK signaling pathways, as well as to the electron 
transport chain, oxidative stress and glucose metabolism 
biological processes, we have drawn a global interaction 
network (Figure 6). It contained 198 (13.8%) multi-
process genes, with 31 (AKT2, CALM1, CALM2, CALM3, 
FOXA2, G6PC, HRAS, IKBKB, INSR, IRS1, MAPK1, 
MAPK3, MAPK8, MLYCD, PDK4, PRKAA1, PRKACA, 
PRKACB, PRKACG, PRKCG, PRKCZ, RAF1, SHC1, 
G6PD, PLA2G4A, SIRT1, SOD1, TNF, CASP3, EGFR and 
MAPK14) genes participating to 3 processes, 7 (FOXO1, 
INS, MAP2K1, MAPK9, PRKCA, PRKCB and NFKB1) 
genes participating to 4 processes and 2 (AKT1 and 
Table 1: The list of highly up-regulated and down-regulated genes with a neuronal function detected 
in human control pancreas and pancreas with type 2 diabetes (T2D) using mRNA expression. 
Protein ID Protein description pI Mw (Da) Gene name Pan-T2D vs Pan-
Cont (fold change)
Q8TAK6 Oligodendrocyte transcription factor 1 9.71 27,905 OLIG1 38.0
O95817 BAG family molecular chaperone regulator 3 6.46 61,595 BAG3 34.2
Q9UKW4 Guanine nucleotide exchange factor VAV3 6.64 97,776 VAV3 −246.8
P32239 Gastrin/cholecystokinin type B receptor 10.03 48,419 CCKBR −89.7
Q9HAZ2 PR domain zinc finger protein 16 5.81 140,251 PRDM16 −81,5
P02647 Apolipoprotein A1 5.56 30,778 APOA1 −65.7
P14138 Endothelin-3 6.24 25,454 EDN3 −55.0
Q6ZMI3 Gliomedin 8.10 58,957 GLDN −43.0
Q9UBU3 Appetite-regulating hormone 5.35 12,911 GHRL −37.0
P61073 C-X-C chemokine receptor type 4 8.46 39,746 CXCR4 −32.7
Protein accession number, protein description, pI (isoelectric point), the Molecular weight (Mw), gene name of that protein, 
and fold change (Pancreas-T2D vs Pancreas-Control) are presented for each gene in this Table. The Mw expressed in Da. pI 
resulted from whole amino acid sequence of each protein and is derived from www.expasy.org.
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PPARGC1A) genes taking EGFR, SHC1 and INSR part in 5 
processes. Due to its high node degree [33], BAG3 resulted 
highly central in the whole graph. Among the others, it 
was connected to 8 multi-process genes, including G6PD. 
APOA1 was mostly connected to lipid metabolism-related 
genes, with 3 multi-process genes, including AKT2. SYT4 
was connected to 5 genes of which only 3 were bi-process. 
Half of the VAV3 interactors were multi-process, while 
VGF interacted with 7 genes, including 2 bi-process and 
MAPK3.
The ELISA of SYT4, VGF, BAG3, ApoA1, and 
VAV3 proteins in plasma of 41 human subjects
To confirm the mRNA expression data derived from 
AT and pancreas with and without T2D, we measured five 
proteins SYT4, VGF, BAG3, ApoA1, and VAV3 in four 
different groups of 41 human subjects; 1- Lean (control), 
2- Obese, 3- Obese with T2D without receiving insulin 
(obese+T2D-INS), and 4- Obese with T2D receiving 
insulin (obese+T2D+INS).
SYT4 and VGF proteins
Although the protein concentration of SYT4 was 
not significantly changed in obese, obese-T2D with and 
without receiving insulin human subjects as compared 
to lean group, there was a clear up-regulation trend 
(Figure 7A), which is in agreement with SYT4 gene 
up-regulation. As depicted in Figure 7B, VGF protein 
concentration was significantly increased in both obese-
T2D with and without receiving insulin subjects as 
compared to lean group. Although there was no significant 
difference between obese and lean group, the average of 
VGF protein concentration was clearly higher in obese 
subjects than lean group (Figure 7B).
BAG3, APOA1, and VAV3 proteins
The plasma protein concentration of BAG3 was 
found to be similar in obese, obese-T2D without receiving 
insulin and lean subjects. However, there was a trend 
towards reduction in obese-T2D subjects receiving insulin 
as compared to the other three groups (Figure 8A). The 
protein levels of ApoA1 were not significantly reduced 
in all three experimental groups of patients as compared 
to the control lean group (Figure 8B). However, when 
obese-T2D subjects were injected with insulin, the 
plasma concentration of ApoA1 goes up comparing 
with obese and obese-T2D without injection of insulin 
as displayed in Figure 8B. Plasma VAV3 protein levels 
(Figure 8C) show a similar pattern as ApoA1, which is 
Figure 1: mRNA analysis of highly changed expression of 10 genes with a neuronal function in pancreas and pancreas 
with T2D. After all corrections (see M & M), mRNA expression was expressed as 2log values to prevent false positive gene differences 
between two conditions. Subsequently, Fold-change between pancreas-T2D and pancreas-control was calculated and shown on the Y-axis 
and was obtained from three measurements.
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mirrored by down-regulation of ApoA1 and VAV3 genes. 
All statistical analysis obtained by ANOVA and ANCOVA 
was summarized in Table 3.
DISCUSSION
Aging can be expressed simply as “functionality 
reduction of biological process” or as “loss or reduction 
of the regulated cell function”. Of note, the aging process 
can be distinguished between early or premature aging and 
regulated (normal) or healthy aging. Thus, all diseases such 
as obesity, IR, diabetes, degenerative disease, and cancer 
could be just referred to aging or aging-related diseases. The 
discovery of the factors responsible for premature aging 
or healthy aging will provide us information to correct 
premature aging or extend healthy aging [23].
Although the underlying mechanisms for the 
development of human T1D (autoimmune disease) are 
completely different from T2D, insulin signaling pathway, 
glucose levels, and energy storage components are 
involved in both types of diabetes. Both age-induced T1D 
and T2D are associated with many complications such 
as DNs. We hypothesized that AT and pancreas could be 
involved in the development of DNs in age-related T2D. 
AT is important during the insurgence of insulin resistance 
in the frame of obesity and produce factors involved in 
energy metabolism, such as chemokines/cytokines, and 
the pancreas is implicated in insulin production. There is 
little known about the genes involved in DNs in these two 
organs (with or without T2D). This study was designed to 
select only genes with very highly up-regulated or down-
regulated in AT and pancreas with age-related T2D (the 
cut off was adjusted to ≥ 32 (=25) times). This selection 
criterion was chosen to prevent false positive gene 
differences between control and T2D in these two organs 
of human.
Overall, 10 genes with a neural function were found 
in pancreas-T2D of which 8 genes were highly down-
regulated and 2 genes highly up-regulated. Although it is 
difficult from our studies to infer about the mechanism 
behind each gene in the development of DNs, we assume 
that these 10 genes could be potentially major players in 
DNs.
One of the functions of CXCR4 is known to regulate 
neuronal signaling and promotes hippocampal-neuron 
survival [34–38], while the mutation affected the gene and, in 
turn, suppression of CXCR4 function. Thus, down-regulation 
Figure 2: 24 neuronal functions related to the 10 genes found in pancreas based on Gene Ontology database 
search. Neuronal processes related to the 10 genes are numbered from 1 to 24 (left side of Figure) and corresponded with numbers 1 to 24 
shown in pancreas Figure. Abbreviations are in Tables 1 and 2. 
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of CXCR4 function may lead to the promotion of neuronal 
apoptosis. Of note, the CXCR4 was down-regulated in 
pancreas-T2D. Neuronal survival and regulation of neuronal 
signaling by CXCR4 might be reduced in T2D patients, 
and this may play a critical role in the development of DNs. 
Moreover, Based on Gene Ontology database search, 17 hits 
with neuronal function were found for CXCR4.
To date, apolipoprotein A-1 (APOA1) was shown 
to be synthesized in the liver and in the small intestine 
and it is a major constituent protein of plasma high-
density lipoprotein (HDL). APOA1 plays a major role 
in reverse cholesterol transport, as it has a high capacity 
to drive cholesterol efflux [39–41]. Intriguingly, APOA1 
was highly expressed in control pancreas but highly 
down-regulated in pancreas-T2D. Several studies have 
shown that the mutation in APOA1 is involved in the 
pathogenesis of polyneuropathy [42–46]. Also, APOA1 
convincingly plays a role not only in the early stage but 
also in late neuropathy [42–46]. These studies support our 
finding that APOA1 is highly down-regulated in pancreas-
T2D, and it is involved in 6 neural processes.
GHRL is also known as appetite-regulating hormone; 
it is highly down-regulated in pancreas-T2D and shows 2 
neural functions. GHRL has been reported to protect neurons 
from damage and to improve neurons survival [47]. This may 
suggest that a down-regulation of GHRL could result in a 
decreased neural protection and neural survival [47].
OLIG1, also known as oligodendrocyte transcription 
factor 1, is very highly up-regulated in pancreas-T2D 
with four neural function hits and is involved in the 
formation of oligodendrocytes and together with OLIG2 
establish precursor motorneuron (pMN) of embryonic 
neural tube [48]. Based on literature search, we could 
only find one study related to up-regulation of OLIG1 and 
disease [49]. In this study, OLIG1 was highly expressed 
in oligodendrogliomas and considered as biomarker for 
glial brain tumors. Thus, the up-regulation of OLIG1 in 
pancreas-T2D suggests that new studies are crucial to 
better elucidate OLIG1 function (s).
The major action of VAV3 (also guanine nucleotide 
exchange factor (GEF)) is in angiogenesis and it has 
been recently shown that loss of VAV3 in mice on chow 
diet resulted in liver steatosis and age-induced T2D [50]. 
Surprisingly, when the same mice were fed a high fat 
diet, they showed resistance against diet-induced obesity 
and metabolic syndrome [51]. However, our findings 
Table 2: The list of highly up-regulated and down-regulated genes with a neuronal function detected 
in human control adipose tissue (AT) and AT-T2D using mRNA expression
Protein ID Protein description pI Mw (Da) Gene name AT-T2D vs AT-CONT 
(fold change)
Q9H2B2 Synaptotagmin-4 8.72 47,958 SYT4 362.08




Q9NQC3 Reticulon-4 4.42 129,931 RTN4 49.36
P18509 Pituitary adenylate cyclase-activating 9.83 18,835 ADCYAP1 48.92
P21246 Pleiotrophin 9.66 18,942 PTN 46.90
P37088 Amiloride-sensitive sodium channel alpha 7.47 75,704 SCNN1A 46.59




Q9P2J2 Protein turtle homolog A 6.74 126,58 IGSF9 35.06
O15240 Neurosecretory protein 4.76 67,258 VGF −119.29
P24530 Endothelin B receptor 9.15 49,644 EDNRB −41.21
P47928 DNA-binding protein inhibitor ID-4 8.69 16,622 ID4 −38.44
Q9UBY5 Lysophosphatidic acid receptor 3 9.53 40,128 LPAR3 −35.62
O14531 Dihydropyrimidinase-related protein 4 6.64 61,878 DPYSL4 −35.47
Q7Z5W6 lamininA 1 7.02 60,711 LAMA1 −34.41
Q9UIU6 Homeobox protein SIX4 5.45 82,933 SIX4 −34.09
Protein accession number, protein description, pI (isoelectric point), the Molecular weight (Mw), gene name of that protein, 
and fold change (AT-T2D vs AT-Control) are presented for each gene in this Table. The Mw expressed in Da. pI resulted 
from whole amino acid sequence of each protein and is derived from www.expasy.org.
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in humans do not support the data collected from mice 
deficient in VAV3. VAV3 showed a down-regulated of 
approximately 246-fold in human pancreas with T2D 
as compared to control pancreas. This finding indeed 
suggests that the action of VAV3 in human is completely 
different from that in mice with manipulated VAV3 gene: 
the restoration of VAV3 in pancreas-T2D could contribute 
to less severe DNs.
In AT-T2D, 8 genes were highly up-regulated and 7 
genes down-regulated with neuronal hits. It is beyond the 
scope of this study to unravel and discuss the individual 
mechanism of each gene in the development of DNs. We 
assume that these 15 genes could be potentially major 
players in DNs. This study provides preliminary evidence 
for further investigations.
SYT4 (Synaptotagmin-4) and VGF (neurosecretory 
protein) genes are dramatically up-regulated and down-
regulated in AT-T2D, respectively. SYT4 is mainly 
detectable in brain and neuroendocrine system and it has 
been suggested to have a neuroendocrine role [52, 53]. 
These authors showed that up-regulation of SYT4 blocked 
the release of oxytocin, which in turn resulted in an obese 
phenotype [52, 53]. On the contrary, down-regulation of 
SYT4 normalized oxytocin release, indicating that obesity 
and its afflictions are under regulation of hypothalamic 
neuropeptides [52, 53]. Based on our novel finding 
(overexpression of SYT4 in AT-T2D) and intriguing 
finding by Zhang et al. [52], we hypothesize that SYT4 
can be used as a new biomarker for obesity and T2D and 
may be considered as prognostic marker for age-induced 
T2D, and negative regulation of SYT4 could potentially 
repair or reduce the degree of DNs.
The main function of VGF (also called neuro-
endocrine regulatory peptide (NERP)) is synaptogenesis 
and they are mainly present in neuron and neuroendocrine 
cells [53–55]. Body fluid homeostasis was also maintained 
by VGF through regulation of vasopressin release 
[54, 55]. Moreover, VGF or VGF-derived peptides 
increase lipolysis in AT and in turn energy consumption 
in VGF deficient mice (knock-out), which are lean 
[56]. However, VGF was highly down-regulated in AT-
T2D, which does not support the results obtained from 
VGF knock-out mice [56]. These contradictory results 
could be due to specific differences between mice and 
humans. Based on this evidence, we speculate that the 
VGF up-regulation (e.g. by an agonist) together with 
Figure 3: mRNA analysis of highly changed expression of 15 genes with a neuronal function in AT and AT with 
T2D. After all corrections (see M & M), mRNA expression was expressed as 2log values to prevent false positive gene differences between 
two conditions. Subsequently, Fold-change between AT-T2D and AT-control was calculated and shown on the Y-axis and was obtained from 
two measurements.
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Figure 4: 52 neuronal functions related to the 15 genes found in AT based on Gene Ontology database search. Neuronal 
processes related to the 15 genes are numbered from 1 to 52 (left side and below of AT Figure) and corresponded with numbers 1 to 52 
shown in AT Figure. Abbreviations are in Tables 1 and 2.
Figure 5: Functional interaction networks of the 5 most differentially expressed genes between AT and AT with T2D, 
and pancreas and pancreas with T2D. Reviewed interactions of SYT4, VGF, BAG3, APOA1, and VAV3 with genes participating to 
a list of critical biological processes and molecular functions (top-left) [source: BioGRID 3.2]. Nodes of networks are genes, while edges 
are interactions. Nodes are colored according to the functions/processes they participate in. Genes taking part in multiple processes are 
colored in cyan. Gene expression levels are represented by bars. Synaptotagmin-4 (SYT4), neurosecretory protein VGF (VGF), BAG family 
molecular chaperone regulator 3 (BAG3), apolipoprotein A-1 (APOA1), and guanine nucleotide exchange factor VAV3 (VAV3).
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down-regulation of SYT4 could restore the homeostatic 
balance between energy consumption and energy storage 
regulation, which could repair or reduce DNs.
Of note, the gene-expression data do not have enough 
power without the confirmation of gene product (i.e. 
protein). For this reason, five from 25 genes was selected to 
measure their protein levels. SYT4 and VGF proteins were 
chosen from AT-associated 15 genes, because SYT4 gene was 
highest and VGF lowest expressed in AT-T2D respectively. 
Although plasma VGF protein concentration in three groups 
of patients did not correspond with VGF gene expression, 
both plasma SYT4 and VGF protein concentrations were 
increased and decreased in obese-T2D with insulin injection 
as compared to without insulin injection in human subjects 
respectively. The effect of insulin was also observed for 
BAG3, APOA1 and VAV3 in obese-T2D with and without 
insulin injection in human subjects. Based on these data, 
it is then logic to assume that insulin has an effect on the 
concentrations of these five proteins and this role of insulin 
could be considered as so-called “corrector’’. Importantly, 
VGF gene expression did not correspond to VGF protein 
levels and one reason could be that post translational 
modifications (PTMs) determine VGF protein levels and 
not transcriptional phase. Although we did not observe any 
significant differences between three patient groups and 
lean subjects with respect to SYT4, BAG3, APOA1, and 
VAV3, except for VGF protein, there was a trend between 
the expression of these four genes and their protein levels.
The majority of investigations and drug 
developments for DNs conducted so far focused on 
glucose metabolic pathways. Neuropathies still remains a 
great problem in patients with diabetes. The expression of 
APOA1 in control pancreas and severe down-regulation 
in pancreas with T2D is very novel and important finding, 
Figure 6: In-silico functional enrichment analysis of 25 differentially expressed genes between AT and AT with T2D, 
and pancreas and pancreas with T2D. Functional network wiring 25 differentially expressed genes between AT and AT with T2D, 
and pancreas and pancreas with T2D drawn by Ingenuity Pathway Analysis. Colored glyphs are genes. Octagons and crosses are relevant 
functions and disorders, respectively. Edges represent interactions between genes or participation of genes to functions. Dashed edges are 
indirect interactions.
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Figure 7: The analysis of SYT4 and VGF proteins in four different groups of 41 human subjects by ELISA. Panel A. 
ELISA was used to measure synaptotagmin-4 (SYT4) protein in 4 different groups of patients; 1- lean (dark green triangle), obese (dark 
blue triangle), 3- obese with T2D without receiving insulin (light violet triangle) and 4- obese with T2D receiving insulin (red triangle). 
All samples were measured in duplicate and blind. The X-axis shows the four different groups of patients. The Y-axis shows the SYT4 
concentration expressed as pg/ml. Panel B. ELISA was used to measure neurosecretory protein VGF (VGF) protein in 4 different groups 
of patients; 1- lean (dark green triangle), obese (dark blue triangle), 3- obese with T2D without receiving insulin (light violet triangle) and 
4- obese with T2D receiving insulin (red triangle). All samples were measured in duplicate and blind. The X-axis shows the four different 
groups of patients. The Y-axis shows the VGF concentration expressed as pg/ml. The p-value resulted from one-way analysis of variance 
(ANOVA). P < 0.05 was accepted as statistically significant.
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Figure 8: The analysis of BAG3, APOA1 and VAV3 proteins in four different groups of 41 human subjects by 
ELISA. Panel A. ELISA was used to measure BAG family molecular chaperone regulator 3 (BAG3) protein in 4 different groups of 
patients; 1- lean (dark green triangle), obese (dark blue triangle), 3- obese with T2D without receiving insulin (light violet triangle) and 
4- obese with T2D receiving insulin (red triangle). All samples were measured in duplicate and blind. The X-axis shows the four different 
groups of patients. The Y-axis shows the BAG3 concentration expressed as ng/ml. Panel B. ELISA was used to measure apolipoprotein 
A-1 (APOA1) protein in 4 different groups of patients; 1- lean (dark green triangle), obese (dark blue triangle), 3- obese with T2D without 
receiving insulin (light violet triangle) and 4- obese with T2D receiving insulin (red triangle). All samples were measured in duplicate and 
blind. The X-axis shows the four different groups of patients. The Y-axis shows the APOA1 concentration expressed as μg/ml. Panel C. 
ELISA was used to measure guanine nucleotide exchange factor VAV3 (VAV3) protein in 4 different groups of patients; 1- lean (dark green 
triangle), obese (dark blue triangle), 3- obese with T2D without receiving insulin (light violet triangle) and 4- obese with T2D receiving 
insulin (red triangle). All samples were measured in duplicate and blind. The X-axis shows the four different groups of patients. The Y-axis 
shows the VAV3 concentration expressed as ng/ml.
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which open new avenues on lipid metabolism, HDL, 
cardiovascular events, diabetes and its complications such 
as neuropathies, and will help to design new future studies. 
GHRL and VAV3 are also expressed in pancreas and 
subjected to extreme level changes in pancreas-T2D. SYT4 
and VGF were synthesized in AT and the levels alter in AT-
T2D dramatically. Based on this study, we conclude that 
not only diabetes but also its complications such as DNs 
are multifactorial diseases. Also, this study provides us a 
list of most important genes affected by diabetes involved 
in neuronal processes, which opens new avenues for new 
investigations for drug development (using agonists or 
antagonists) and new pathway(s) for the treatment of DNs.
MATERIALS AND METHODS
Human biopsies and gene expression procedures
Total RNA was isolated from human adult normal 
visceral AT and AT-T2D. Total RNA was collected from 
5 pooled human normal pancreases and one pancreas 
with T2D provided by AMS Biotechnology (Amsbio, 
England). The quality and concentrations of RNAs were 
assessed in a Bioanalyzer (Experion), (Bio-Rad, USA/
The Netherlands) using the Agilent RNA 6000 Nano kit 
(Agilent, The Netherlands). Amplification Kit was applied 
to amplify and label the RNA (Applied Biosystems, 
The Netherlands). Total RNA was reverse-transcribed 
into cDNA, and the concentrations were determined in 
NanoDrop. RNA Amplification Kit (Ambion, USA) was 
used to biotinylate cRNA according to the manufacturer’s 
instructions. Samples were purified using the RNeasy kit 
(Qiagen, The Netherlands). Hybridization to the Sentrix 
Human Expression BeadChip, washing, and scanning 
were performed according to the BeadStation 500 manual 
(revision C). One BeadChip with 12 samples was used. 
Each slide was scanned immediately. After the scanning, 
the following steps were performed: 1: quality check; 
2: background correction; 3: normalization to house-
keeping genes; and 4: utile normalization of the data using 
Beadstudio Expression module v 3.2.7. After these 4 steps, 
a relative mRNA intensity of 2log was considered cut-off. 
Each pancreas sample was three times and AT samples 
two times measured. The methods were carried out in 
“accordance” with the approved guidelines.
Human subjects and plasma collection
41 human subjects divided into four groups of 10 
(except lean group 11 subjects), independent of age and 
gender, as follows: Group 1-Lean subjects with a body 
mass index (BMI) between 20.1 and 25.6 kg/m2, Group 
2- Obese subjects with a BMI greater than or equal to 
30 kg/m2, Group 3- Obese subjects with T2D without 
receiving insulin (obese+T2D-INS) and a BMI greater 
than or equal to 30 kg/m2 30 and Group 4- Obese subjects 
with T2D, receiving insulin (obese+T2D+INS) and BMI 
greater than or equal to 30 kg/m2. All patients were well-
selected based on their BMI. Blood was drawn from each 
subject after informed consent by venipuncture into tubes 
containing Ethylene Diamine Tetra Acetic Acid (EDTA) 
as anticoagulant. Subsequently, plasma was isolated by 
centrifugation at 1500× g for 15 min at 4°C and stored at 
–80°C for further analysis.
The measurement of protein concentrations 
of SYT4, VGF, BAG3, APOA1, and VAV3 by 
ELISA
96-well microtitration plates (NuncSorb) were 
coated with primary antibodies (100 μl at 5 μg/ml in 
PBS, 4°C). After four washes with PBS, the wells are 
saturated with BSA (200 μl, 3% in PBS, at least 2 h at 
RT). After four washes with PBS, 25 μl of each human 
Table 3: Characteristics and protein concentrations of research population groups (n = 41) 
n (%), mean (±SD)




Obese + T2D – INS
(n = 10)
Obese + T2D + INS
(n = 10)
Gender: n (Male %) 3 (27) 3 (30) 2 (20) 5 (50)
Age (years) 34.09 (±8.08) 45.20 (±6.23) 56.26 (±10.54) 67.18 (±6.97)
SYT4 (pg/ml) 24.95 (±1.64) 26.28 (±3.01) 25.71 (±2.66) 26.68 (±4.09)
VGF (pg/ml) 212.27 (±80.57) 261.20 (±85.74) 309.80 (±105.99) 330.60 (±78.93)
VAV3 (ng/ml) 4.75 (±1.64) 5.14 (±1.81) 4.53 (±1.31) 5.25 (±1.69)
apoA-1 (μg/ml) 11.20 (±2.72) 10.23 (±3.32) 8.88 (±2.35) 10.76 (±3.56)
BAG3 (ng/ml) 2.32 (±0.69) 2.01 (±0.90) 1.93 (±0.87) 2.06 (±1.29)
Subjects categorized into four groups including: lean (20.1 ≤ BMI ≤ 25.6 kg/m2), obese (BMI ≥ 30 kg/m2), obese with 
T2D without receiving insulin (obese+T2D-INS) and obese subjects with T2D receiving insulin (obese+T2D+INS). 
Protein concentrations were normally distributed and were presented as mean±SD.
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serum sample were deposited in the wells and protein 
were allowed to bind to their specific mAb during 3 h at 
RT. All proteins not specifically bound were eliminated 
by four washes with PBS. Then the HRP-conjugated 
secondary antibodies were added (100 μl at 1 μg/ml in 
PBS, 45 min at RT). After four washes with PBS, 100 μl 
of HRP substrate (TMB: 3,3′,5,5′-tetramethylbenzidine; 
Thermo Scientific Pierce) were deposited and reaction 
was allowed during 15 min in dark (upon oxidation, TMB 
forms a water-soluble blue reaction product that can be 
measured spectrophotometrically at 650 nm). Reaction 
was then stopped by addition of 100 μl H2SO4 2 M (upon 
acidification, the reaction product becomes yellow with 
an absorbance peak at 450 nm). Absorbance at 450 nm 
(yellow) was monitored on a plate-reader device. Primary 
antibodies were purchased from SIGMA (SYT4, APOA1, 
BAG3), from Santa Cruz Biotechnology (VAV3) and 
Abcam (VGF). HRP-coupled secondary antibodies (anti-
mouse, anti-goat, anti-rabbit) were purchased from Abcam.
Interaction network-based pathway analysis
Genes belonging to lipid metabolism, insulin, protein 
kinase C, advanced glycation end (AGE) products and 
MAPK signaling pathways, together with those participating 
to the electron transport chain, oxidative stress and glucose 
metabolism biological processes were collected [57–58]. 
Considering that correlation of gene expression and protein 
to protein interactions have been shown to cluster genes of 
similar function [59], we queried UniProtKB, Mentha [60], 
STRING [61] and BioGRID [62] in search of any evidence 
of connection between these genes and BAG3, APOA1, 
VGF, VAV3 and SYT4. Interactions were represented as 
edges of graphs, while nodes denoted genes, as already 
explained in [63]. Genes were colored according to the 
biological processes/pathways they were participating in. 
Light blue nodes represented genes that took part to 
multiple processes and pathways. Differential expressions 
of BAG3, APOA1, VGF, VAV3 and SYT4 genes between 
normal and patient samples were evaluated by unpaired 
student t-test at significance level of α = 5%. A global 
view of the functional involvement of the 25 genes into 
the abovementioned critical processes and pathways has 
been further obtained by the Ingenuity Pathway Analysis 
workbench. A gene-function mixed network was generated, 
where edges corresponded to literature-confirmed scientific 
evidences of interaction between any two genes. Dashed 
edges represented indirect interactions. Green colored genes 
were down-regulated in our case-study, while red genes 
were up-regulated. Molecule shapes correspond to as many 
kinds of molecules, as for functions or diseases (octagons 
and crosses).
Statistics
ANOVA was performed as statistical analysis to 
identify the protein levels of SYT4, VGF, VAV3, APOA1 
and BAG3 for each BMI group (1- lean, 2- obese, 
3- obese+T2D-INS and 4- obese+T2D+INS).
Analysis of covariance (ANCOVA) was used to 
identify differentially proteins concentrations of SYT4, 
VGF, VAV3, apoA1, and BAG3 across the four groups as 
controlling for the effects of confounding variables including 
age and gender. ANCOVA analysis was done using change 
of proteins concentrations in groups as dependent variable; 
ordinal variable of four groups (lean, obese, obese- T2D-
INS, obese-T2D+INS) as a fixed effect and the effects 
of confounders were controlled in analysis as covariates 
(Table 3). The choice for a post-hoc analysis was due to 
having five proteins profiles across four groups. All statistical 
tests were two-sided and performed at a significance level of 
α = 5%. Data analyses were performed using SPSS statistical 
software (version 22; SPSS Inc., Chicago, USA).
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